Testing a gene therapy for vestibular schwannoma
Original title: Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing whether a single dose of a gene therapy is safe.
Who this trial is for. This trial is for people with vestibular schwannoma. It tests one dose of a gene therapy called AAVAnc80-antiVEGF, given on one side at one of three dose levels.
Where it stands. The trial has not reported results. It is measuring whether the therapy is safe and how well people handle it. It is also checking the Akouos device used to give the therapy. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Someone with vestibular schwannoma could ask their care team about this trial. The team can say if it fits their case. An early trial like this mainly looks at safety, not at how well the therapy works.
What it doesn't mean: This does not mean the therapy works. A trial is a test, not a proven treatment. Being in one is not a guarantee of any benefit. It is not a cure.
Source: ClinicalTrials.gov, November 4, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.